Premium
The adjuvant effect of a non‐toxic mutant of heat‐labile enterotoxin of Escherichia coli for the induction of measles virus‐specific CTL responses after intranasal co‐immunization with a synthetic peptide
Author(s) -
PARTIDOS C. D.,
PIZZA M.,
RAPPUOLI R.,
STEWARD M. W.
Publication year - 1996
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1046/j.1365-2567.1996.d01-790.x
Subject(s) - heat labile enterotoxin , enterotoxin , adjuvant , nasal administration , immunization , measles virus , mutant , ctl* , virology , microbiology and biotechnology , escherichia coli , biology , measles , immunology , vaccination , immune system , gene , genetics , cd8
The intranasal route has been shown to be effective for immunization. However, immunization via this route may require the use of potent and safe adjuvant. The construction of non‐toxic mutants of heat labile enterotoxin of Escherichia coli (LT), which is a potent mucosal adjuvant, is a major breakthrough for the development of mucosal vaccines. In this study we have assessed the ability of an LT mutant (LTK63) to act as an adjuvant following intranasal co‐immunization with a peptide corresponding to a measles virus cytotoxic T lymphocyte (CTL) epitope. LTK63 was more effective at potentiating the in vivo induction of peptide‐specific and measles virus‐specific CTL responses than was administration of the peptide in saline. A concentration of 10 μg/dose of LTK63 was found to be the most effective in potentiating the in vivo priming of peptide‐specific and measles virus‐specific CTL responses. These findings highlight the potential of the non‐toxic mutant of LT as a safe mucosal adjuvant for use in humans.